Active Pharmaceutical Ingredient– tag –
-
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Evonik Breaks Ground on Biotechnology Expansion in Slovakia, Strengthening European Pharmaceutical Manufacturing Hub
Evonik Germany Overview On September 14, 2026, Evonik initiated construction for a significant biotechnology manufacturing expansion at its Fermín site in Slovakia. This investment aims to bolster the company's production capacity for ac... -
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
Swiss Bachem Invests Over $431M in 2026 to Meet Surging Global Peptide and Oligonucleotide Demand with New Facility
Pharma Manufacturing Switzerland Overview Bachem, a Swiss CDMO specializing in peptides and oligonucleotides, is undertaking a major manufacturing capacity expansion across its global network, investing between $431 million and $493 mill... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Hongene Biotech: Scaling Oligonucleotide Manufacturing Crucial for Surging siRNA Demand in Cardiometabolic Diseases
Hongene Biotech China Overview Hongene Biotech emphasizes the critical need for a dramatic scale-up in oligonucleotide manufacturing to meet the surging demand for siRNA therapeutics targeting cardiometabolic diseases. Driven by the succ... -
PharmTech Analyzes Mid-2026 Key Trends: AI Integration in Drug Discovery and Manufacturing, Strengthened Supply Chains, and New Drug Approvals
PharmTech USA Overview PharmTech released its 'Midyear 2026 Check-in' report, analyzing key pharmaceutical industry trends: AI integration in drug discovery and manufacturing, reinforced supply chain resilience, and new drug approval dyn...
12